Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 16 AL 30

Alzheimer's and type 2 diabetes treatment via common enzyme targeting

Jabir NR, Kamal MA, Abuzenadah AM, Gan SH, Alama MN, Baeesa SS, Tabrez S.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):299-304. doi: 10.2174/18715273113126660145.

The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications

Zemva J, Schubert M.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):322-37. doi: 10.2174/18715273113126660141.

Insulin-degrading enzyme: a link between Alzheimer's and type 2 diabetes mellitus

Haque R, Nazir A.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):259-64. doi: 10.2174/18715273113126660139.

Common cellular and molecular mechanisms underlying Alzheimer's disease and type 2 diabetes: a knowledge-driven approach

Gauthaman K, Pushparaj PN, Rajeshkumar M, Narasimhan K, Al-Qahtani M, Cheung NS, Manikandan J.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):247-58. doi: 10.2174/18715273113126660138.

Molecular linkages between diabetes and Alzheimer's disease: current scenario and future prospects

Dar TA, Sheikh IA, Ganie SA, Ali R, Singh LR, Gan SH, Kamal MA, Zargar MA.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):290-8. doi: 10.2174/18715273113126660135.

Fighting Alzheimer's disease and type 2 diabetes: pathological links and treatment strategies

Dai Y, Kamal MA.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):271-82. doi: 10.2174/18715273113126660134.

Editorial: current update on association between Alzheimer's disease and type 2 diabetes: volume I

Kamal MA.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):192-6. doi: 10.2174/1871527313999140307101350.

Sleep in frontotemporal dementia is equally or possibly more disrupted, and at an earlier stage, when compared to sleep in Alzheimer's disease

Bonakis A, Economou NT, Paparrigopoulos T, Bonanni E, Maestri M, Carnicelli L, Di Coscio E, Ktonas P, Vagiakis E, Theodoropoulos P, Papageorgiou SG.

J Alzheimers Dis. 2014;38(1):85-91. doi: 10.3233/JAD-122014.

Anesthetics and its impact on the brain and Alzheimer's disease

Mandal PK, Ritchie K, Fodale V.

J Alzheimers Dis. 2014;39(2):223-5. doi: 10.3233/JAD-131487.

The effects of different antioxidants on the activity of cerebrocortical MnSOD and Na,K-ATPase from post mortem Alzheimer's disease and age-matched normal brains

Kairane C, Mahlapuu R, Ehrlich K, Zilmer M, Soomets U.

Curr Alzheimer Res. 2014 Jan;11(1):79-85. doi: 10.2174/15672050113106660179.

Subcellular injuries in Alzheimer's disease

Tillement JP, Papadopoulos V.

CNS Neurol Disord Drug Targets. 2014;13(4):593-605. doi: 10.2174/18715273113126660197.

Disruption of zinc homeostasis and the pathogenesis of senile dementia

Kawahara M, Mizuno D, Koyama H, Konoha K, Ohkawara S, Sadakane Y.

Metallomics. 2014 Feb;6(2):209-19. doi: 10.1039/c3mt00257h.

Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies

Sopova K, Gatsiou K, Stellos K, Laske C.

Curr Alzheimer Res. 2014 Jan;11(1):27-39. doi: 10.2174/1567205010666131120100743.

Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease

Rodrigues Simões MC, Dias Viegas FP, Moreira MS, de Freitas Silva M, Riquiel MM, da Rosa PM, Castelli MR, dos Santos MH, Soares MG, Viegas C Jr.

Mini Rev Med Chem. 2014 Jan;14(1):2-19. doi: 10.2174/1389557513666131119201353.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias